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Abstract The peritoneal metastatic route of cancer dissem-
ination is shared by cancers of the ovary and gastrointestinal
tract. Once initiated, peritoneal metastasis typically pro-
ceeds rapidly in a feed-forward manner. Several factors
contribute to this efficient progression. In peritoneal metas-
tasis, cancer cells exfoliate into the peritoneal fluid and
spread locally, transported by peritoneal fluid. Inflammatory
cytokines released by tumor and immune cells compromise
the protective, anti-adhesive mesothelial cell layer that lines
the peritoneal cavity, exposing the underlying extracellular
matrix to which cancer cells readily attach. The peritoneum
is further rendered receptive to metastatic implantation and
growth by myofibroblastic cell behaviors also stimulated by
inflammatory cytokines. Individual cancer cells suspended
in peritoneal fluid can aggregate to form multicellular
spheroids. This cellular arrangement imparts resistance to
anoikis, apoptosis, and chemotherapeutics. Emerging evi-
dence indicates that compact spheroid formation is prefer-
entially accomplished by cancer cells with high invasive
capacity and contractile behaviors. This review focuses on
the pathological alterations to the peritoneum and the prop-
erties of cancer cells that in combination drive peritoneal
metastasis.
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1 Introduction
Intraperitoneal dissemination is the primary metastatic route
of ovarian cancers. It is also a common progression for
gastrointestinal malignancies including colorectal, gastric,
and pancreatic cancers, for which it signifies a grim prog-
nosis [1, 2]. The poor prognosis relates, in large part, to the
rapid progression of peritoneal metastasis in comparison to
the hematological (blood-borne) metastatic route. This latter
route, recently reviewed [3, 4], is a more laborious process
that involves cancer cell penetration of multiple barriers
during intravasation and extravasation from blood vessels,
as well as growth in a foreign environment. The distinct
mechanisms involved in peritoneal metastasis contribute to
its devastating efficiency, and are the focus of this review.
While all cells within the ovary can give rise to malignan-
cies, epithelial ovarian cancers (EOC) are the most common
and lethal. EOCs are a heterogeneous group of cancers that
may be categorized into two major groups [5]. Type I EOCs
are low-grade, slow-growing tumors that are thought to arise
from benign ovarian lesions and include all four major histo-
types: serous, endometrioid, mucinous, and clear cell. While
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DOI 10.1007/s10555-012-9351-2the cell of origin for these cancers remains controversial, a
favored model is that they develop from the ovarian epitheli-
um. Whensegmentsoftheovariansurfaceepitheliumorother
Mullerian-derived epithelia become entrapped within cortical
inclusion cysts in the ovary, they are exposed to a hormone-
rich environment that promotes the tumorigenesis of cells
possessing oncogenic mutations (e.g., KRAS, BRAF, β-
catenin, or TGFβRII). In contrast, type II EOCs may be
derived from the secretory cells of the fallopian tube epithelia
and have tubal rather than ovarian precursor lesions. Type II
EOCs frequently have p53 mutations and are, hence, geneti-
cally unstable and present histologically as high-grade serous,
mixed epithelial, or undifferentiated carcinomas. These can-
cers are thought to seed the ovarian surface and pelvic perito-
neum concurrently, which explains why they rarely present as
stage I disease [5].
EOCs generally have an insidious onset. Due to the
asymptomatic nature of early-stage disease, most patients
are not diagnosed until after their tumors have metastasized
intraperitoneally. At this point, their chance of surviving
beyond 5 years is only about 25 % [6], which is largely
due to the diffuse peritoneal lesions that impede surgical
eradication. In fact, the completeness of surgical debulking
is the best predictor of survival. Chemotherapy, while ini-
tially effective, ultimately fails to prevent disease progres-
sion because patients almost inevitably develop recurrent
resistant disease [7, 8].
Intraperitoneal metastases can cause peritoneal organ ad-
hesion and malfunction, massive ascites, and/or pleural effu-
sions [9–11], leading to mortality. In contrast, the
hematological metastatic route is not a significant contributor
toEOCmortality[12],reflectingtherelativeeaseandspeedof
cancer dissemination and growth in the peritoneal cavity.
Colorectal and gastric cancers can metastasize through hema-
tological,lymphatic,orintraperitonealroutes.Theseepithelial
cancers typically arise on the luminal/mucosal side of the
gastrointestinal tract, which is well separated from the serosal
(peritoneal) membrane. However, cancer cells can shed di-
rectly into the peritoneal cavity for tumors that breach the
submucosa, smooth muscle, and serosal layers. Alternatively,
accidentalperforation ofthe intestinalwall duringsurgerycan
introduce cancer cells from tumors that were previously not
exposed to the peritoneal space. Irrespective of the means of
introduction, peritoneal involvement drastically worsens the
prognosis for these patients [13, 14].
A key factor contributing to the poor prognosis of intra-
peritoneally metastasizing cancers is the rapid, self-
perpetuating, feed-forward cycle of seeding and growth that
is fuelled by inflammation. Since the prognosis of patients
with peritoneal metastases is tightly correlated with the
completeness of surgical cytoreduction [15, 16], and wide-
spread metastases are not amenable to surgery, the develop-
ment of novel strategies to arrest metastatic progression is
imperative. This review summarizes the current understand-
ing of mechanisms involved in peritoneal metastasis, with a
focus on altered cell–cell and cell–matrix dynamics.
2 The peritoneum is receptive to metastatic growth
The mechanisms involved in peritoneal metastasis are dis-
tinct from those of the hematological route. Relative to
hematological metastasis, peritoneal metastasis is a passive,
efficient process that occurs locally in a self-perpetuating,
feed-forward cycle. This presents unique challenges to
intervention.
The peritoneal cavity is particularly receptive to metasta-
sis, as evidenced by several key observations. First, al-
though EOC cells are detected in the circulation at
relatively early stages of disease [12], metastatic deposits
outside of the peritoneal cavity are rare and not a common
cause of morbidity. Overwhelming evidence for the tumor-
receptive environment can be gleaned from cases where
pressure from massive ascites was relieved using a perito-
venous shunt. This procedure introduced vast numbers of
malignant cells into the circulation, yet it did not place
patients at increased risk of mortality. Postmortem autopsies
revealed either a lack of extraperitoneal metastasis, or when
present, lesions that were small and clinically asymptomatic.
This surprising finding indicates that cancer cells capable of
metastasis in the abdominal cavity are incapable of signifi-
cant growth in other tissues, supporting the notion that the
peritoneal environment is receptive to cancer seeding [17].
Additional evidence that the peritoneal environment
provides a privileged site for cancer metastasis is
reflected in prognostic data. Colorectal carcinoma prog-
nosis is dramatically worsened by accidental bowel per-
foration during surgery [18, 19], a mishap that can
directly introduce cancer cells into the peritoneal cavity.
In gastrointestinal cancers including gastric, appendiceal,
colonic, and rectal, the involvement of the serosal mem-
brane (which is synonymous to, and contiguous with, the
peritoneal surface) is one of the most important determi-
nants of overall prognosis [14]. In gastric cancer, the
presence of tumor cells in peritoneal lavages is a predic-
tor of decreased survival time, whereas micrometastases
in lymph nodes or bone marrow are of limited prognos-
tic value [20]. For endometrial cancer, there are recent
cautions that the practice of diagnostic hysteroscopy,
which involves increasing intrauterine pressure using
distension media, may retrogradely drive cancer cells
into the peritoneal cavity through the fallopian tubes,
thereby increasing the risk of metastasis [21]. Collective-
ly, these observations strongly support the peritoneum as
a particularly receptive environment for cancer metasta-
sis and growth.
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Cancercells canfreelydisseminate inthe peritoneal cavityafter
exfoliating from exposed primary intraperitoneal tumors: ovar-
ian epithelia for type I EOC, fallopian tube epithelia for type II
EOC, and the serosal membrane for colorectal or gastric can-
cers. Theyalso gainaccess when introducedthroughaccidental
surgical perforation of the bowel wall [22]. In either case, once
suspended in the peritoneal fluid, the cancer cells must resist
anoikis, a specialized form of apoptosis triggered by a lack of
attachment to other cells or to the extracellular matrix (ECM).
They must also evade clearance through the peritoneal lym-
phatics. By attaching to the peritoneal membrane, cancer cells
avoid both anoikis and clearance. Accordingly, interactions
between tumor cells and the peritoneum are key contributors
to metastatic progression, which, if successfully blocked,
should promote the clearance or death of cancer cells.
4 Cellular and molecular properties of the peritoneum
The peritoneum is comprised of a single layer of mesothelial
cells and its associated underlying ECM, which cover the vast
surface of the abdominal and pelvic cavities, as well as vis-
ceral organs (∼1.7 m
2, comparable to the surface area of the
skin). Mesothelial cells apically secrete glycosaminoglycans
(primarily hyaluronan), surfactant (mainly phosphatidylcho-
line) and proteoglycans to provide an anti-adhesive peritoneal
surface that ensures the appropriate gliding of the abdominal
viscera and prevents intra-abdominal organ fusion [23]. Intra-
abdominaladhesions are a complicationthatfrequentlyoccurs
with peritoneal surgery due to the unavoidable disruption of
this fragile mesothelial layer [24]. Consistent with their anti-
adhesive functioning, mesothelial cells also protect against
cancer cell attachment, which will be further discussed.
Mesothelial cells regulate the entry of leukocytes and
inflammatory cells into the peritoneal cavity. In response
to injury or insult, these cells release chemokines MCP-1
and IL-8 and upregulate cell surface adhesion molecules
ICAM-1 and VCAM-1, to which leukocytes attach [25].
Mesothelial cells possess both epithelial and mesenchymal
characteristics and readily undergo epithelial–mesenchymal
transformation (EMT) and myofibroblast transformation in
response to normal tissue repair and pathological stimuli
[23]. The ECM underlying the peritoneal mesothelial cells is
richincollagenIandfibronectin,withthindepositsoflaminin
and collagen IV lying directly beneath the mesothelium [26].
The ECM is, for the most part, concealed by the flattened
squamous-like mesothelial cell layer; however, it is periodi-
cally exposed at the lymphatic portals through which the
peritoneal fluid drains into the venous circulation. These lym-
phatic portals are particularly abundant on the omental and
sub-diaphragmatic peritoneal surfaces and are commonly
referred to as “milky spots” because of their whitish appear-
ance that results from the accumulation of resident lympho-
cytes participating in immune surveillance [25].
Ultrastructural analysis reveals the absence of a basement
membrane at milky spots. Instead, the collagen I-rich stromal
matrix is exposed. The adjacent mesothelial cells have a
cuboidal morphology with disruptions and intercellular gaps
that further expose the peritoneal ECM. This cuboidal mor-
phology likely reflects activation by cytokine secretions from
the neighboring milky spot lymphocytes [23, 27].
5 Cancer cell attachment to the peritoneum
Metastasizing cancer cells have two main options for attach-
ment to the peritoneum: the surface mesothelial cells or the
exposed ECM. Many investigations have focused on the
mechanisms mediating cancer cell attachment to a cultured
mesothelial monolayer. Some studies suggest that the mecha-
nisms normally used for leukocyte attachment to mesothelial
cells may be exploited by cancer cells. Ovarian, colorectal,
and pancreatic cancer cells bind to mesothelial cell surface
receptors ICAM-1 and/or VCAM-1 [28–30], which are upre-
gulated in response to injury or insult [25]. As well, the
hyaluronan receptor CD44, expressed by many cancer cell
types including ovarian and gastric cancer cells, enables these
cells to bind to the hyaluronan-rich apical surface of mesothe-
lial cells [31–34]. The ovarian cancer biomarker CA125/
MUC16 is a transmembrane mucin that binds to mesothelin,
a GPI-linked protein expressed by mesothelial cells [35].
Hence, a variety of different adhesion molecules can mediate
the attachment of cancer cells to mesothelial monolayers.
Attachment of cancer cells to the ECM, on the other hand, is
mainly mediated by integrins. The β1 integrin subunit is key
as it can pair with a variety of α-integrin subunits to confer
binding to most ECM substrata. Blocking β1 integrin inhibits
EOC cell attachment and migration on ECM substrata rele-
vanttotheperitoneum[36,37].β1integrinsalsoparticipatein
cancercellattachmenttomesothelial monolayers[33, 37–39],
which could reflect that cancer cells are binding to the
mesothelium-associated ECM and/or to mesothelial cell sur-
face VCAM-1, as outlined above. Cancer cell lines display
differential reliance on specific adhesion molecules. There-
fore, the specific cell lines and in vitro model system selected
have greatly influenced study conclusions.
Ensuring that the in vitro models are an accurate repre-
sentation of the in vivo events is crucial for identifying
meaningful targets for intervention. Many studies have been
designed with the assumption that peritoneal metastasis
relies on cancer cell attachment to mesothelial cells. How-
ever, other studies indicate that cancer cells have a much
greater affinity for the peritoneal ECM, which is consistent
with the clinical pattern of metastatic spread.
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Several lines of evidence indicate that mesothelial cells
protect against, rather than mediate, cancer cell attach-
ment. Collagen I, a major constituent of the sub-
mesothelial ECM [26], is the preferred substrate for ovar-
ian cancer cell attachment [40] and migration [37, 41].
Moreover, collagen I binding activates EOC cell invasive
behavior [42]. EOC cell lines with an aggressive pheno-
type have an elevated expression of the α2a n dβ1
collagen-binding integrin subunits as compared to cells
with lower invasive capacity [43]. For gastric cancer cells,
peritoneal invasion was inhibited by blocking the collagen
I-binding integrin α2β1[ 44]. Hence, the mesothelial lay-
er actively discourages cancer cell attachment by occlud-
ing the underlying collagen I-rich extracellular matrix to
which cancer cells preferentially attach (Fig. 1).
Surgical trauma and stress damage the mesothelium and
expose the underlying ECM, creating privileged sites for
cancer cell attachment [45, 46]. The benefit of peritoneal
lavage following surgery to wash out exfoliated tumor cells
may be countered by the damage to the fragile mesothelial
cell layer that enhances metastasic spread [47]. The en-
hanced peritoneal invasion that occurs in response to surgi-
cal trauma is mediated by β1 integrins [48]. In support of
the concept that mesothelial cells discourage rather than
mediate cancer cell attachment, Kenny et al. [49] deter-
mined that cancer cell adhesion to a 3D reconstituted omen-
tal stromal matrix was inhibited when an overlying layer of
mesothelial cells was included in the model. Conversely,
cancer cell adhesion to ex vivo omental tissue was markedly
elevated when the mesothelial layer was removed.
The clinical pattern of disease progression underscores
the concept that cancer cells preferentially attach to areas
where the mesothelium is disrupted. During the initial stages
of peritoneal metastasis, cancer cells attach to milky spots
where the collagen-rich connective tissue matrix is exposed
[50–53] (Fig. 1a). The resident immune cells of the milky
spots are not able to prevent tumor growth [50, 54]; instead,
their production of pro-inflammatory cytokines promotes
cancer growth and dissemination. The abundance of milky
spots within the omentum might explain the predilection of
cancer cells to seed this structure. The omentum also con-
tains a large number of adipocytes that may promote the
growth of the attaching cancer cells by providing lipids to
meet their energy demands [55].
7 Inflammatory alterations render the peritoneum
susceptible to tumor cell adhesion
Secretions from cancer, stromal, mesothelial, and immune
cells, particularly macrophages, contribute to an
inflammatory environment that drives peritoneal metastasis
[56–58]. Consistent with the action of soluble inflammatory
cytokines and chemokines, widespread alterations in gene
expression reflecting a more adhesive peritoneum were
found in peritoneal tissue from patients with EOC [59, 60].
The impact of inflammatory cytokines on peritoneal me-
tastasis is profound and transforms the initial pattern of
dissemination, which is limited to milky spots, into a wide-
spread peritoneal metastasis [51, 61]. This transformation is
triggered by an increased exposure of the sub-mesothelial
ECM, driven by inflammation. The inflammatory cytokines,
tumor necrosis factor alpha (TNFα) and interleukin 1β
(IL1β) cause the protective mesothelial cells to retract,
exposing the previously obscured underlying ECM. Since
cancer cells preferentially attach to the ECM, widespread
cancer cell attachment ensues [51, 61] (Fig. 1b).
TNFα is highly expressed by cancer and inflammatory
cells [51, 62, 63], and its levels are elevated in peritoneal
effusions of ovarian cancer patients [64]. The associated
retraction and uplifting of mesothelial cells is characteristic
of EOC patients [65]. In addition to causing mesothelial
retraction, TNFα and other inflammatory mediators upregu-
late ICAM-1 and VCAM-1 adhesion molecules on meso-
thelial cells, which facilitates cancer–mesothelial cell
interactions [30]. Despite this, when cancer cells were added
to a monolayer of mesothelial cells that had been pretreated
with TNFα, the cancer cells attached to the intracellular
gaps where the sub-mesothelial collagen I matrix was ex-
posed rather than to the mesothelial cells [51]. This finding
underscores the preference of the cancer cells to attach to the
collagen-rich ECM.
In light of the preference of cancer cells for the sub-
mesothelial matrix, it is unclear why blocking interactions
between cancer cells and mesothelial cells impedes metas-
tasis in experimental models. Antibody-mediated inhibition
of CD44 [34, 66] for ovarian and colorectal cell lines
expressing high levels of CD44, or of VCAM [30], slowed
the progression of peritoneal metastasis in mice. In these
experiments, the blocking agents were administered simul-
taneously with a large bolus of cancer cells to mice that
presumably had a healthy, intact peritoneal mesothelial lay-
er. This is in marked contrast to the situation in most patients
who present with advanced disease and peritoneal inflam-
matory alterations.
Collectively, the evidence supports an inhibitory role of
the mesothelium in peritoneal cancer cell attachment
(Fig. 1). While activated mesothelial cells may be less
efficient at creating a barrier than a quiescent mesothelial
monolayer, in either case, these cells protect against cancer
cell adhesion by concealing the underlying connective tissue
matrix to which cancer cells preferentially attach. Knowing
that cancer cells prefer areas where the mesothelium is
absent and the peritoneal ECM is exposed highlights the
400 Cancer Metastasis Rev (2012) 31:397–414importance of targeting cancer cell interactions with the
ECM while simultaneously preventing mesothelial cell
retraction.
8 Ascites formation contributes to peritoneal metastasis
Ascites, an accumulation of protein-rich exudate within the
abdominal cavity, is a complication that often accompanies
cancers metastasizing within the peritoneum. In EOC, asci-
tes is frequently a presenting feature of advanced-stage
disease, and although it often resolves following chemother-
apy, it generally re-accumulates in chemo-resistant and re-
current disease. In other cancers, ascites is a late event when
the goal of treatment is palliation [67]. Ascites facilitates a
widespread dissemination of cancer cells in the abdominal
cavity [68] and has been correlated with a poor prognosis. In
a study limited to patients with stage III/IV EOC, women
without ascites had a 5-year survival rate of 45 % compared
to 5 % for those with ascites [69].
Clinically, ascites is a distressing and debilitating compli-
cation that significantly impacts quality of life [70]. The
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Fig. 1 Changing patterns of
metastatic spread with disease
progression. a Cancer cells
initially attach to milky spots
where the stromal matrix is
exposed, providing direct
access to their preferred
substrate, collagen I. The intact
mesothelial layer discourages
cancer cell attachment. b With
disease progression and in
response to increasing
concentrations of inflammatory
mediators, mesothelial cells
retract and detach. The resulting
exposure of the underlying
ECM, with a discontinuous
basement membrane, facilitates
widespread peritoneal
metastasis. TGF-β, released by
cancer and inflammatory cells,
stimulates myofibroblast trans-
differentiation. c Metastasizing
cancer cells, particularly those
with a highly invasive, contrac-
tile phenotype, form compact
spheroids in peritoneal fluid.
This protects them against
anoikis and chemotherapeutics.
These spheroids attach to and
invade the peritoneal matrix.
The combination of their con-
tractile and proteolytic capaci-
ties remodels the collagen I-rich
matrix to facilitate stromal im-
plantation and invasive growth
Cancer Metastasis Rev (2012) 31:397–414 401volume of ascites varies widely among patients, ranging from
<100 mL to in excess of 10 L quantities that can cause
considerable discomfort and contribute to organ dysfunction.
In cases where massive re-accumulation of ascites occurs, as
is common with chemo-resistant EOC, repeated paracentesis
fortemporarypalliationisrequired.Removaloflargevolumes
of ascitic fluid carries with it the risk of hypovolemic shock
and contributes to the development of inanition, while repeat-
ed paracentesis increases the risk of bowel perforation and
peritonitis. Diuretics may be administered, and, in rare cases,
peritoneo-venous shunts or indwelling drainage catheters are
surgically installed to enable drainage. Unfortunately, there is
no established gold standard for the clinical management of
malignant ascites [71, 72].
The pathophysiology of ascites accumulation involves
increased net filtration and/or decreased drainage of perito-
neal fluid; that is, fluid production is more rapid than its
clearance [73]. Ascites thus can arise through multiple pro-
cesses, including the blockage of lymphatic channels drain-
ing the peritoneum by metastatic cells, increased
permeability of capillaries within the peritoneal wall due in
large part to the actions of VEGF, decreased protein levels in
the blood resulting in increased fluid movement to the
abdominal cavity, and hepatic portal vein compression or
liver failure due to massive liver metastasis. Notably, it is the
tumor-free peritoneal surface that provides the majority of
the surplus fluid in cancer-associated ascites [74].
A positive feedback cycle of cytokine release that involves
cancer, mesothelial, and inflammatory cells contributes to
ascites [75]. In EOC, cancer cells secrete VEGF-A and mono-
cyte chemoattractant protein-1, which attract monocytes that
contribute more VEGF-A (plus other cytokines and growth
factors). VEGF-A increases vascular permeability and neo-
vascularization. A largebodyofevidenceimplicatesVEGFin
ascites formation [75–78] (reviewed in [79]). Accordingly,
aflibercept, a soluble circulating VEGF receptor decoy that
acts as a VEGF trap, holds promise for the relief of malignant
ascites based on the outcomes of two recent clinical trials [80,
81], the latter of which was a randomized, double-blind
placebo-controlled study.
A cellular mechanism by which VEGF increases vascular
permeability has recently been revealed [82]. VEGF binding
to its receptor activates focal adhesion kinase (FAK) which
localizes to the cytoplasmic tail of VE-cadherin at endothe-
lial cell–cell junctions. FAK phosphorylates β-catenin,
which destabilizes the cell–cell junctions, resulting in in-
creased vascular permeability (Fig. 2).
Cancer-associated ascites is enriched in other growth
factors and pro-inflammatory factors secreted from cancer,
reactive stromal, and inflammatory cells that contribute to
the aforementioned peritoneal inflammatory alterations that
promote cancer cell attachment. These include IL-8 [61, 83],
IL-6 [84], TNFα [64], TGFβ, IL-12, and IL-10 [76], hepa-
tocyte growth factor (HGF) [85], heparin-binding epidermal
growth factor (HB-EGF) [86], and lysophosphatidic acid
(LPA) [87]. Several of these factors as well as others found
in ascites may promote chemoresistance [83, 88, 89]. Inter-
estingly, ascites from different patients was found to have
variable effects on the motility of ovarian cancer cells, with
a subset of these samples containing a heat-sensitive inhib-
itory substance [90]. Fibrinogen and fibrin also enter the
peritoneal cavity in increased amounts during ascites forma-
tion [91]. In contrast to the beneficial effect of fibrin depo-
sition in immune defense, where it serves to help entrap
VEGF
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FAK-inactive
FAK-active
P
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β-catenin
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Fig. 2 VEGF-induced vascular
permeability leads to the
accumulation of ascites. Tumor
cells secrete VEGF and
chemokines such as MCP-1 that
attract macrophages, which se-
crete additional VEGF. VEGF
binds to its receptor on vascular
endothelial cells in the perito-
neal wall, leading to the activa-
tion of focal adhesion kinase
(FAK). Activated FAK binds to
the tail of the VE-cadherin that
mediates endothelial cell–cell
junctions and phosphorylates
β-catenin, triggering its release
which destabilizes these junc-
tions [82]. The resulting in-
crease in vascular permeability
is a major contributor to ascites
formation and accumulation
402 Cancer Metastasis Rev (2012) 31:397–414intraperitoneal bacteria [76], fibrin deposition is detrimental
in the case of peritoneal cancer because it entraps metasta-
sizing tumor cells, leading to the formation of aggregates
that become vascularized metastatic deposits in a process
facilitated by the elevated VEGF-A and IL-8 [91].
9 Proteolysis in peritoneal metastasis
Peritoneal metastasis, in contrast to hematologic metastasis,
does not require cancer cells to degrade matrix barriers
associated with intravasation and extravasation of the vas-
culature. Rather, peritoneal metastasis entails cell adhesion,
highly variable degrees of invasive growth and/or carpet-
like spreading on peritoneal surfaces. The degree of inva-
sion into the stroma varies and may be related to EOC grade
and histotype, although the determinants of invasive behav-
ior are undoubtedly multifactorial. Irrespective of invasive
depth, proteolysis is required for cancer cells to anchor and
establish metastatic implants.
Cancer cell interactions with basal lamina components are
probably not a prime determinant of peritoneal metastasis
since the cancer cells have direct access to their preferred
substrate, the fibrillar collagen I-rich peritoneal stroma, at
milky spots and in areas exposed by mesothelial cell retrac-
tion.Thecollagenolyticmatrixmetalloproteinase(MMP)sub-
set, which includes MMP-1, MMP-8, MMP-13, and the MT-
MMPs, is therefore implicated in invasion. While the impor-
tance of MMPs in EOC metastasis is recognized [92, 93],
clinical trials using the broad-range MMP inhibitors marima-
stat and tanomastat have yielded disappointing results
[94–96]. This likely relates to the fact that the inhibitor con-
centrations attained were far below levels required to accom-
plish the inhibition of critical MMPs [97, 98]. Moreover,
certain MMPs can, depending on the microenvironmental
context, counter tumor progression such that their inhibition
would be counterproductive [99]. Thus, a more targeted ap-
proach that accomplishes the inhibition of specific cancer-
promoting MMPs should be of therapeutic advantage [100].
A deterministic role for the transmembrane subgroup of
MMPs (MT-MMPs) has been revealed for cancer cell trans-
migration through stromal and basement membrane matri-
ces, which pose protease-dependent barriers to cell
migration in vivo (reviewed by [101]). MT-MMPs acting
at the leading edge of invading cells effect a focal pericel-
lular proteolysis of the matrix barriers while leaving the
matrix sufficiently intact to support cell migration. Soluble
MMPs do not cleave fibrillar collagens in a manner that is
conducive to cancer cell invasion, but may facilitate this
process by cleaving cell surface receptors or by generating
bioactive products in the surrounding stroma [101].
MT1-MMP (MMP-14) has been revealed as a critical
determinant of EOC cell invasion through collagen I
matrices [102] where cell capacities for invasion reflected
those reported in vivo in an intraperitoneal xenograph mu-
rine model [103]. MT1-MMP was also revealed to be an
important mediator of peritoneal metastasis by gastric can-
cer cells, and the authors noted that metastasis by cancer
cells lacking MT1-MMP was rare [104].
Studies using collagen I [87, 90] and extensive studies by
Weiss and colleagues using ex vivo peritoneal membrane
and mammary gland explants [82, 83] exclude the need for
soluble MMPs in matrix invasion by cancer cells. However,
MMP-2 was reported to enhance the early adhesion of
ovarian cancer cells to the peritoneum by cleaving fibronec-
tin and vitronectin to create a superior substratum for α5β1
and αvβ3 integrin binding [105]. As MT1-MMP is the key
activator of pro-MMP-2 [106], this implies an additional
mechanism for its contribution to peritoneal metastasis.
In addition to degrading the ECM and activating soluble
MMPs, MT1-MMP promotes peritoneal metastasis through
its sheddase activity. One such target is the transmembrane
epidermal growth factor HB-EGF. This growth factor has a
prominent role in peritoneal metastasis, and its elevated
expression is correlated with a poor clinical outcome
[107]. HB-EGF overexpression confers intraperitoneal
metastatic ability to cancer cells that were otherwise inca-
pable of metastasis. Conversely, its inhibition greatly
reduces intraperitoneal metastatic progression [108].
CRM197, a mutated diphtheria toxin that specifically binds
and inactivates HB-EGF, and inhibits peritoneal metastasis
in mice, is now in phase I clinical trial [109]. HB-EGF is
shed by ADAMs (a disintegrin and metalloproteinase) to
release an active soluble growth factor that is fully active
only when bound to heparan sulfate proteoglycans. This
soluble fragment can be further cleaved by MT1-MMP to
generate a dually processed potent form that does not re-
quire heparan cofactors for activity [110]. This potent form
of HB-EGF is present in EOC patient ascites [111]. The
invasive growth of gastric and ovarian cancer cells, as well
as their anchorage-independent growth depends on MT1-
MMP-mediated HB-EGF cleavage [110, 111]. Efforts to
develop small-molecule inhibitors of MT1-MMP have been
stimulated by compelling evidence that this protease drives
the progression of multiple cancer types [112]. As these
specific inhibitors become available, it will be possible to
better assess the role MT1-MMP in peritoneal metastasis.
10 Cell contractility promotes metastasis
Cells maintain a reciprocal dialogue with their surrounding
ECM through integrin receptors which indirectly link the
ECM to the actin cytoskeleton. Integrin activation can be
mediated by growth factor “inside-out” activation or ECM-
mediated “outside-in” activation. The clustering of activated
Cancer Metastasis Rev (2012) 31:397–414 403integrins triggers signaling cascades involving FAK, Src,
PI3K, RhoA, Rho kinase (ROCK), and myosin regulatory
light chain (MLCK) phosphorylation, culminating in
actinomyosin-mediated cell contractility, which transmits
forces that alter the ECM. Tissue homeostasis is dependent
on a balance between ECM deposition and turnover. When
this delicate balance is disrupted by growth factors and
cytokines associated with wounding or cancer, a feed-
forward cycle of increased ECM deposition, rigidity, and
cell contractile behavior ensue, which perpetuates peritoneal
metastasis in several ways, as discussed below.
The dense, rigid matrices formed through excessive col-
lagen deposition and actomyosin-mediated contraction
strongly promote cell proliferation and tumorigenesis
[113–117]. Rigid matrices facilitate cancer metastasis by
supporting scattering behavior. The stronger “foothold” they
provide enables integrin-associated actomyosin forces to
overcome and sever cell–cell attachments, a prerequisite to
the emigration and invasion of individual cells [117, 118].
Cell-mediated contraction also contributes to metastasis in a
3D environment by re-orientating collagen fibers into “high-
ways” that are used as tracks for cancer cell migration and
invasion [119, 120]. In support of this concept, invasive
regions of tumor explants remodeled their surrounding
ECM to achieve a radial orientation of collagen fibrils, upon
which they migrated [121]. Similarly, ovarian cancer cell
lines with robust contractile behavior were the only ones
capable of migrating through 3D collagen I matrices [122].
Contractile behavior by surrounding stromal cells can
also facilitate metastasis. Force-mediated matrix remodeling
by fibroblasts was required for squamous cell carcinoma cell
invasion through a mixed collagen I-based matrix [123].
Moreover, ovarian cancer cell invasion though a reconsti-
tuted omentum was enhanced when fibroblasts were includ-
ed in the collagen I matrix, an effect that could not be
recapitulated by substituting fibroblast-conditioned media.
While the authors speculated that cell–cell contact between
cancer and fibroblast cells was involved in the enhanced
migration [49], an alternative possibility is that matrix con-
traction by the fibroblasts, perhaps in response to stimula-
tion by the cancer cells, contributed to a reorganization of
the matrix that promoted cancer cell invasion. The cells best
known for matrix deposition and contractility, myofibro-
blasts, are associated with many tumor types, including
ovarian [124, 125], and are known to drive cancer progres-
sion [126, 127].
11 Derivation of tumor-associated myofibroblasts
Tumor-associated myofibroblasts originate from several
precursor cell types, including fibroblasts, mesothelial cells,
and cancer cells, and contribute to ECM alterations that
promote metastasis. Fibroblast–myofibroblast transdifferen-
tiation is a well-recognized phenomenon that contributes to
numerous pathologies [126, 127]. In the case of cancer,
factors secreted by cancer cells initiate the myofibroblast
transdifferentiation through a process that involves chloride
intracellular channel 4 (CLIC4) upregulation as a prerequi-
site to the expression of the myofibroblast marker alpha
smooth muscle actin (αSMA) [128]. TGF-β is a key acti-
vator of the transdifferentiation of fibroblasts into myofibro-
blasts. This cytokine is secreted by many cancer cell types,
including ovarian, and contributes to the upregulation of
αSMA [125, 129].
The transdifferentiation of mesothelial cells into myofibro-
blasts is also stimulated by TGF-β. This process is commonly
observed in peritoneal dialysispatients and leads to loss of the
mesothelium, fibrosis, and peritoneal membrane failure [130,
131]. A similar transdifferentiation could explain the loss of
mesothelial and fibroblast cells and the gain of αSMA-
positivemyofibroblastsatsitesofinvasivetumorimplantation
in the peritoneum [132]. Bone marrow-derived circulating
cells and endothelial cells are also activated by TGF-β and
contribute to the peritoneal myofibroblast population [131].
Moreover, there is compelling evidence that epithelial cancer
cells transdifferentiate into myofibroblast-like cells in an
EMT-dependent process [133].
12 Contractile behavior enhances cancer cell survival
by promoting compact spheroid formation
Contractile behavior may be particularly beneficial for the
survival of cancer cells during peritoneal metastasis. When
suspended individually during transit in the peritoneal fluid,
cancer cells are susceptible to anoikis and other apoptotic
triggers. However, by combining with other suspended cells
to form compact multicellular “spheroid” aggregates, these
cells can resist anoikis and apoptosis, including that induced
by chemotherapeutics. The abundance of integrin attach-
ments available to cells within the 3D spheroid configura-
tion is thought to be a major contributor to pro-survival
signaling [134, 135].
Spheroids, which range from 50 to 750 μm in size [38],
are commonly found in the peritoneal fluid or ascites of
EOC patients, independent of histotype [136]. As a source
of viable metastatic cells, spheroids readily adhere to and
disaggregate on ECM substrates, particularly collagen I, as
well as on mesothelial cell monolayers [36, 37]. A growing
recognition of the importance of spheroids in EOC dissem-
ination has stimulated increased interest in their formation
and function. An intriguing positive association between
contractile behavior, compact spheroid-forming ability, and
the invasive capacity of cancer cells in 3D compliant matri-
ces has been revealed [122].
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Cancer cells possess varying capacities for spheroid formation
[38, 122,137]. Whereas a positive correlation between spheroid
formation and tumorigenicity has been suggested [137], an
inverse association between spheroid cohesiveness and invasive
potential has been reported for brain tumor cells [138]. The
possibility that cells in spheroids gain invasive properties by
undergoing EMT while in a spheroid arrangement has been
proposed [139]. However, compact spheroid formation was
found to be accomplished only by EOC cell lines that already
possessed a mesenchymal phenotype. These cell lines also had a
superior migratory and invasive capacity compared to the cell
lines that didnotform compact spheroids,properties that existed
prior to, as well as subsequent to, spheroid formation [122].
These results suggest that an aggressive cancer cell subpopula-
tion is able to gain a survival advantage through its propensity
for compact spheroid formation. Any further enhancement of
invasivepotentialgainedwithinthespheroidmicroenvironment,
as proposed [139], would add to this detrimental scenario. A
likely basis for the relationship between compact spheroid for-
mation and cell migration/invasion within 3D compliant matri-
ces is that both processes rely on contractile cell behavior [122].
14 Mechanisms involved in spheroid formation
As a first step in spheroid formation, cells must interact with
one another either directly or through ECM bridges. An ECM
network interconnects EOC cells within spheroids [38], and
integrin attachments to fibronectin, collagen, and Matrigel
support spheroid formation by different cancer cell types [38,
140–143]. Direct cell–cell attachments through homotypic
cadherin associations can also mediate spheroid formation
[140, 144]. Hence, a variety of cell adhesion mechanisms can
mediate the initial aggregation of cancer cells into spheroids.
The compaction of aggregated cells into dense spheroids
is dependent upon the contractile capacity of the cells [122].
A similar phenomenon, the compaction of spheroid-like
microtissues and toroid formations [145], is mediated by
actinomyosin forces. Both integrins and cadherins have
been implicated in spheroid formation, and as each provides
links to the actin cytoskeleton to transmit actomyosin-
mediated forces, it is likely that actomyosin-mediated con-
traction is universally involved in spheroid compaction.
15 Malignant ascites promotes compact spheroid
formation
ECM molecules, growth factors, and cytokines present in
ascites, including fibronectin, TGF-β,H G F ,E G F ,a n dL P A ,
promote cell adhesion and motility [56, 146] and induce
contractile behavior by fibroblasts [118, 147–149]. EOC cells
thatotherwisedonotformcompactspheroidsareabletodoso
when the tissue culture media (containing 10 % serum) is
supplemented with ascites from a patient with high-grade
serous EOC (Fig. 3a). Since ascites supplementation also
enabled their collagen gel contraction (Fig. 3b), it is likely
that the stimulation of cell contractility by ascites was an
important contributor to the enhanced spheroid formation.
Notably, the collagen gel contraction and spheroid formation
promoted by ascites in the EOC cell lines normally incapable
of these behaviors was modest compared to the abilities
possessed by contractile, invasive EOC cell lines [108], even
in the absence of ascites exposure. Thus, while ascites com-
ponents can augment these behaviors, the genetic program of
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Fig. 3 Ascites promotes compact spheroid formation and contractile
behavior by human ovarian cancer cell lines otherwise incapable of
these behaviors. a Enhanced spheroid formation by human ovarian
cancer cell lines, SKOV-3 and OVCAR-3, in response to treatment
with malignant ascites from a patient diagnosed with advanced epithe-
lial ovarian cancer. Spheroids were formed by the hanging drop meth-
od and culture medium (containing 10 % serum) was supplemented
with ascites (1:1, v/v). Images were obtained after 3 days. b Enhanced
collagen gel contraction by SKOV-3 and OVCAR-3 cells in response
to treatment with malignant ascites. Cells were mixed with collagen
type I (Vitrogen) for a final concentration of 5×10
5 cells/1.6 mg
Vitrogen per milliliter. Results are shown at 4 days (left panel) and
10 days (right panel). While ascites had a pronounced effect on these
parameters, these changes were modest compared to the compact
spheroid formation and collagen gel contraction exhibited by the more
invasive cell lines in the absence of ascites [122]
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contractile and spheroid forming capacity.
16 Cell contractile behavior provides protection
against chemotherapeutics
In solid tumors, contractile behavior creates dense rigid ma-
tricesthatconferdrugresistanceby(1)increasingthepotential
for integrin attachments and their associated pro-survival sig-
naling [116] and (2) generating a high interstitial hydrostatic
pressurethathindersdrugdelivery[150].Contractilebehavior
would also endow chemoresistance to intraperitoneally dis-
seminating cancer cells by promoting their incorporation into
compact spheroids. Cells in spheroids are known to have an
enhanced resistance to many antitumor chemotherapeutics.
This phenomenon of “multicellular resistance” has been at-
tributed to multiple mechanisms, including a decreased pene-
trance of therapeutics, decreased cell proliferation, increased
pro-survival integrin signaling, and an upregulation of genes
conferring drug resistance [134, 135, 151, 152].
Strong support for a role of compact spheroid formation in
conferring drug resistance is provided by a study that com-
pared drug-resistant cells to their parental cell lines. Cells
selected for drug resistance in vivo showed a striking ability
to form compact spheroids as compared to their parental cells.
Moreover, their enhanced resistance to chemotherapeutics
was evident in vitro only when they were compared to the
parental cells as a spheroid culture. When cultured as mono-
layers, differences in drug resistance were admonished [153].
This provides compelling evidence that the chemoprotective
effect was conferred by compact spheroidformation. Coupled
with the evidence that aggressive cancer cells have an in-
creased propensity for compact spheroid formation [122],
and given the challenge of chemoresistant disease in EOC
[154], these studies underscore the importance of preventing
compact spheroid formation as a means of diminishing peri-
toneal metastasis and enhancing the efficacy of current drug
therapies. Since cells can use a variety of potentially redun-
dant mechanisms for their initial aggregation into spheroids
(e.g., integrin–ECM or cadherin-mediated) [140], targeting
this phase is likely to require a multifaceted approach. In
contrast, actomyosin contractility, a likely common denomi-
nator and critical mediator of spheroid compaction, is attrac-
tive as a potential therapeutic target.
17 Targeting actomyosin contractility in peritoneal
metastasis
Cell contractile behavior potentially drives peritoneal cancer
progression through several mechanisms. By inhibiting acto-
myosin contractility, the increases in matrix density and
rigidity that promote malignant progression and interfere with
the delivery of chemotherapeutics could be reduced. More-
over, cells in transit should be sensitized to anoikis andchemo-
therapeuticsifcompactspheroidformationcouldbeprevented.
ROCK plays a major role in cell contractile behavior.
ROCK ensures myosin II remains active and capable of
binding and contracting actin filaments by (1) phosphory-
lating and inactivating myosin regulatory light chain phos-
phatase and (2) promoting myosin regulatory light chain
phosphorylation directly, as well as indirectly by phosphor-
ylating MLCK. ROCK also activates LIM kinase, which
phosphorylates and inactivates cofilins, thus preventing F-
actin severing [155]. Two isoforms of ROCK have been
identified, ROCK1 and ROCK2. These isoforms share high
sequence identity in their kinase domain [156].
The conditional overexpression of ROCK2 in murine
skin increased tissue stiffness and thickening and enhanced
tumor incidence, growth, and progression. These effects
were reversible when ROCK2 or its downstream effectors
(myosin ATPase, LIM kinase) or its upstream activator FAK
was inhibited [117]. The cell behaviors mediated by ROCK,
including cell motility, adhesion, and contraction, have been
implicated in a range of diseases, and the clinical benefit of
ROCK inhibition with Fasudil (HA-1077), which targets
both ROCK isoforms, is under investigation [155].
ROCK1/2 inhibition using Y-27632 interfered with a
process similar to spheroid formation: the cell sorting and
compaction involved in microtissue formation [145]. Y-
27632 protects against TGF-β-induced mesothelial EMT
[157] as well as glucose-induced peritoneal fibrosis [158]
in experiments using a rodent model. This suggests that, at
least for the peritoneal membrane and its stromal counter-
parts, ROCK inhibition could be beneficial for reducing the
inflammatory changes associated with cancer, including
mesothelial retraction.
While it is tempting to speculate that ROCK inhibition
could slow peritoneal metastatic progression by blocking
spheroid compaction and motile behavior of cancer cells,
the observation that ROCK inhibition enabled embryonic
stem cells [159] and prostate stem cells [160]t or e s i s t
anoikis is noteworthy. Establishing the precise outcome of
ROCK inhibition on cancer cell behaviors, under both at-
tached and anchorage-independent/spheroid culture condi-
tions, is therefore crucial.
18 Future perspectives
High-throughput genetic and proteomic approaches hold
promise for the discovery of early-stage disease biomarkers
that may improve survival rates. However, identifying
disease-specific markers capable of heralding early events
in carcinogenesis has been proven to be a formidable
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are urgently required and will continue to be needed, inde-
pendent of gains in our ability for early detection, as screen-
ing approaches cannot be expected to detect all cancers at
early stages. While many ovarian cancers are initially re-
sponsive to current chemotherapeutic approaches, progres-
sion to a drug-resistant form is an almost universal
occurrence. Novel strategies that target cancer cell interac-
tions with the peritoneal ECM and inflammation-driven
peritoneal modifications that expose the peritoneal ECM
are likely to be broadly applicable to cancers that metasta-
size within the abdominal cavity.
A cornerstone to devising strategies to block peritoneal
metastasis is the selection and implementation of suitable in
vitro and in vivo invasion models that accurately mirror the
clinical situation. Cancer cells preferentially attach to and
invade regions of the peritoneum where the sub-mesothelial
ECM is exposed rather than to an intact mesothelium. This
is evident in the pattern of peritoneal metastasis. Initially,
cancer cells disseminate to milky spots where the basement
membrane is disrupted and where they have direct access to
the collagen I-rich connective tissue matrix. Collagen I is
arguably the most important ECM component with which
cancer cells interact during peritoneal dissemination, both
for adhesion and invasion.
Mounting evidence indicates that cell behavior in 3D
culture differs from monolayer culture and better reflects
the in vivo situation [161]. Consideration must be given to
the choice of ECM used in these cultures. Many commer-
cially available collagen I solutions fail to provide a phys-
iologically relevant barrier to cell migration when
reconstituted as 3D gels. For ease of extraction, collagen I
is often proteolytically digested to remove the telopeptide
regions that contain the majority of intra- and intermolecular
collagen I cross-links. As a result, cells can migrate through
this reconstituted matrix in the absence of proteolytic activ-
ity since the matrix comprises a loose collection of collagen
fibrils [98, 162–164]. Similarly, Matrigel, a laminin and
collagen IV-rich extract from Engelbreth–Holm–Swarm tu-
mor cells that is often used as a surrogate basement mem-
brane, is unsuitable for studying cell invasion. Cell
penetration of Matrigel, unlike that of bona fide basement
membranes, occurs in the absence of MMP activity [162,
164, 165]. Basement membrane assembly is a cell-mediated
process that uses precise and extensive covalent cross-
linking and disulfide bond formation to form a stable
sheet-like network of collagen IV. While Matrigel is rich
in laminin and collagen IV, it lacks the stable laminar
organization that is a hallmark of basement membrane ma-
trices [101, 162]. Hence, penetration through Matrigel
assesses cell migration rather than cell invasion.
Collagen I with intact telopeptide regions can be isolated
by acid extraction and reconstituted as a 3D gel that forms a
true (MMP-dependent) barrier to cell transmigration. A limi-
tation is that the density and rigidity found in vivo are not
reflected in vitro due to the limited solubility of collagen,
which is an important consideration in light of compelling
evidence that matrix density and rigidity have fundamental
effects oncell behaviorand differentiation [113, 166, 167].Ex
vivo peritoneal matrices retain a requirement for MMP-driven
invasion as well as a density and complexity that resembles
the in vivo situation [97]. It would be informative to explore
differences in the mechanisms of cancer cell attachment to
membranes obtained from animals with and without pre-
established peritoneal inflammation.
Strategies that block tumor cell interaction with the sub-
mesothelial ECM (rather than the mesothelium itself) should
prove more effective in blocking intraperitoneal metastatic
dissemination atclinicallyrelevantdisease stagessince cancer
cells preferentially adhere to exposed peritoneal ECM. In
addition, minimizing the amount of exposed peritoneal ECM
by preventing mesothelial retraction isan intriguing avenue to
further reduce peritoneal metastasis [168, 169]. If cancer cell–
ECM interactions could be limited by minimizing mesothelial
cell retraction, the approach of blocking mesothelial–cancer
cell interactions would become more relevant.
Cells that gain a survival advantage by forming compact
spheroids likely represent an aggressive subpopulation of
cells, at least for EOC. This underscores the importance of
targeting spheroid formation. Whether invasive capacity and
compact spheroid formation are linked in other intraperito-
neal cancers should be determined. The likelihood that
compact spheroid formation and cancer cell-induced ECM
remodeling both involve cellular contractility presents the
exciting possibility that chemoresistance and invasion can
be simultaneously targeted.
19 Summary
Several events conspire to promote peritoneal metastasis:
1. The peritoneal cavity is highly susceptible to tumor cell
implantation and growth. Cells need only to exfoliate
from primary tumors and secondary sites into the peri-
toneal fluid, which provides efficient transport to addi-
tional sites within the abdominal cavity. The presence of
milky spots/lymphatic ducts, where a basement mem-
brane is lacking and the adhesive collagen-I-rich con-
nective tissue matrix is directly exposed, encourages the
attachment of metastasizing cells.
2. Cancer cells stimulate a pro-inflammatory response
within the peritoneal cavity, which augments metastasis.
Inflammatory mediators cause retraction and uplifting
of the protective mesothelial cell lining, which promotes
cancer cell attachment by exposing the underlying pro-
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myofibroblast transdifferentiation of mesothelial cells
and fibroblasts and initiate a fibrotic response within
the peritoneum. The dense, rigid, fibrotic matrices that
result promote tumor cell survival, growth, invasion,
and chemoresistance by enhancing integrin signaling.
3. MT1-MMP has emerged as an important contributor to
peritoneal metastasis. In addition to its established peri-
cellular collagenolytic activity that is crucial for inva-
sive growth, its conversion of HB-EGF into a more
potent, heparin-independent form, as well as its activa-
tion of soluble pro-MMP-2, likely contribute to its abil-
ity to promote intraperitoneal metastasis.
4. Invasive cancer cells likely attain resistance to anoikis
and chemotherapeutics by virtue of their propensity for
contractile behavior and compact spheroid formation.
This link between cancer cell invasive ability and ca-
pacity for compact spheroid formation highlights the
importance of targeting these multicellular aggregates.
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